A diverse product portfolio, with solid positions in the pharmaceuticals and nutritionals business; Core drugs--Plavix, Avapro, Abilify, Reyataz, and Erbitux--with long remaining patent lives; and A long-standing modest financial risk profile, with ample amounts of liquidity. Rash of major drug patent expirations, including Pravachol in early 2006; and A very hefty annual dividend. The ratings on New York-based Bristol-Myers Squibb Co. reflect its diverse product portfolio, promising new-drug pipeline, and solid financials. Bristol-Myers' portfolio remains diverse, with strong positions in the oncology, cardiovascular, and virology markets. The company's top-five-selling drugs accounted for roughly 45% of total sales in 2005, in line with its peers. Cardiovascular drug Plavix, an anti-platelet aggregator, leads the portfolio. The drug, in-licensed from sanofi-aventis, generated $3.8
